WHAT IS BIOMAP?
Atopic Dermatitis and Psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time, and response to treatment. BIOMAP will examine the causes and mechanisms of Atopic Dermatitis and Psoriasis to enable optimal treatments and an individualized therapy scheme for each patient. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm from reactive to proactive strategies encompassing disease biology and lifetime trajectory, matching the intervention with endotypes. Learn more about BIOMAP.
TWO NEW LAY SUMMARIES PUBLISHED
181 studies were identified investigating biomarkers linked with more extensive psoriasis and/or other linked health conditions such as joint disease. 22 promising biomarkers were selected from included studies, although none were supported by sufficient evidence to be used in current practice without further investigation. Several common limitations of approaches to investigate this important question were highlighted following a detailed evaluation of studies.
Findings can help focus future research efforts to facilitate promising biomarkers being used in clinical practice.
Read the complete publication: Biomarkers of Disease Progression in People with Psoriasis: A Scoping Review
Summary 2: The Search for Measurable Predictors Linked with Safe and Effective Response Treatment in Psoriasis
71 studies were identified investigating biomarkers linked with a less effective response or adverse events to tablet or injectable treatments used for psoriasis. Seven promising genetic biomarkers were identified following a detailed evaluation of the higher-quality studies. These biomarkers were found to play key roles in molecular pathways implicated in psoriasis. Findings from this study can help researchers prioritize biomarkers for future focused investigation to confirm their usefulness in clinical practice.
Read the full publication: Biomarkers of Systemic Treatment Response in People with Psoriasis: A Scoping Review